What neuromodulator should be used as first‑line therapy for functional belching in otherwise healthy adults, and what is the recommended dosing regimen?

First-Line Neuromodulator for Functional Belching

For functional belching (specifically supragastric belching), central neuromodulators should be used in combination with brain-gut behavioral therapies rather than as standalone first-line therapy, with behavioral interventions taking priority. 1

Treatment Hierarchy

The 2023 AGA Clinical Practice Update establishes that behavioral strategies are the most effective treatment for supragastric belching, not neuromodulators alone 1. The guideline explicitly recommends:

• Brain-gut behavioral therapies (BGBTs) as primary treatment, including:

  • Cognitive behavioral therapy (CBT)
  • Diaphragmatic breathing
  • Speech therapy
  • Gut-directed hypnotherapy

• Central neuromodulators are recommended as adjunctive therapy when combined with BGBTs 1

When Neuromodulators Are Appropriate

Neuromodulators should be considered specifically for:

1. Gastric belching associated with GERD - where excessive transient lower esophageal sphincter relaxations (TLESRs) occur
2. Refractory cases after behavioral therapy trials
3. Combination therapy with behavioral interventions for enhanced symptom control

Specific Neuromodulator Choice

Baclofen is the evidence-based neuromodulator for belching disorders when pharmacotherapy is indicated:

• Dosing: 10 mg three times daily 2
• Mechanism: GABA-B receptor agonist that increases lower esophageal sphincter pressure and decreases swallowing rate
• Evidence: Significantly reduces both symptom markers (from average 20 to 6 events) and flow events (from 473 to 282) in patients with supragastric belching 2
• Correlation: Effectiveness correlates with increased LES pressure (r = -0.62) and reduced swallowing frequency (r = 0.64) 2

Critical Pitfalls to Avoid

1. Do not use neuromodulators as monotherapy - The guideline emphasizes that behavioral strategies are most effective, and neuromodulators work best in combination 1

2. Differentiate belching types first - Supragastric belching (voluntary, behavioral) responds to behavioral therapy, while gastric belching related to TLESRs may benefit from baclofen 1

3. Rule out GERD association - If belching occurs after reflux episodes (not before), PPI therapy combined with diaphragmatic breathing is appropriate; supragastric belching before reflux does not respond to PPIs 1

4. Patient education is essential - Psychoeducation about the pathophysiology serves as the critical first step, similar to biofeedback for pelvic floor disorders 1

Algorithmic Approach

1. Confirm diagnosis with impedance-pH monitoring or high-resolution manometry (at least 90 minutes, preferably 24 hours) 1
2. Provide psychoeducation about belching mechanism
3. Initiate behavioral therapy (diaphragmatic breathing, CBT)
4. If GERD-associated with excess TLESRs → Consider baclofen 10 mg TID 1, 2
5. Reserve neuromodulators for combination with behavioral therapy, not as standalone first-line 1

The evidence strongly favors behavioral interventions over pharmacotherapy as first-line treatment, with baclofen reserved for specific indications related to gastric belching and TLESR-mediated symptoms 1, 2.